Endothelin receptor antagonists in cardiology clinical trials

被引：16

作者：

Neunteufl, T ^{[1
]}

Berger, R ^{[1
]}

Pacher, R ^{[1
]}

机构：

[1] Univ Vienna, Sch Med, Dept Cardiol, A-1090 Vienna, Austria

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2002年 / 11卷 / 03期

关键词：

arterial hypertension; clinical trials; congestive heart failure; coronary artery disease; endothelin receptor antagonist; pulmonary hypertension;

D O I：

10.1517/13543784.11.3.431

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients with congestive heart failure and results in coronary vasoconstriction in patients with coronary artery disease (CAD). Moreover, ET-1 raises blood pressure,induces vascular and myocardial hypertrophy and acts as the natural counterpart of nitric oxide (NO), which exerts vasodilating, antithrombotic and antiproliferative effects. This article reviews recently completed and ongoing clinical trials examining the effects of ET receptor antagonists in patients with heart failure, CAD, arterial hypertension and pulmonary hypertension.

引用

页码：431 / 443

页数：13